PL2961391T3 - Preparat zawierający pochodną benzotiazolonu - Google Patents

Preparat zawierający pochodną benzotiazolonu

Info

Publication number
PL2961391T3
PL2961391T3 PL14708700T PL14708700T PL2961391T3 PL 2961391 T3 PL2961391 T3 PL 2961391T3 PL 14708700 T PL14708700 T PL 14708700T PL 14708700 T PL14708700 T PL 14708700T PL 2961391 T3 PL2961391 T3 PL 2961391T3
Authority
PL
Poland
Prior art keywords
formulation
benzothiazolone compound
benzothiazolone
compound
Prior art date
Application number
PL14708700T
Other languages
English (en)
Inventor
Miloud Achour
Robin Alec Fairhurst
Arnaud Grandeury
Shinji Hatakeyama
Magdalena Koziczak-Holbro
Nicola Tufilli
Thomas Ullrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2961391T3 publication Critical patent/PL2961391T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL14708700T 2013-02-28 2014-02-26 Preparat zawierający pochodną benzotiazolonu PL2961391T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361770584P 2013-02-28 2013-02-28
EP14708700.1A EP2961391B1 (en) 2013-02-28 2014-02-26 Formulation comprising benzothiazolone compound
PCT/IB2014/059270 WO2014132205A1 (en) 2013-02-28 2014-02-26 Formulation comprising benzothiazolone compound

Publications (1)

Publication Number Publication Date
PL2961391T3 true PL2961391T3 (pl) 2017-10-31

Family

ID=50238437

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14708700T PL2961391T3 (pl) 2013-02-28 2014-02-26 Preparat zawierający pochodną benzotiazolonu

Country Status (30)

Country Link
US (1) US9623012B2 (pl)
EP (1) EP2961391B1 (pl)
JP (2) JP6230626B2 (pl)
KR (1) KR20150120386A (pl)
CN (1) CN104968337A (pl)
AU (1) AU2014222362B2 (pl)
BR (1) BR112015020059A2 (pl)
CA (1) CA2897565A1 (pl)
CL (1) CL2015001940A1 (pl)
CY (1) CY1119202T1 (pl)
DK (1) DK2961391T3 (pl)
EA (1) EA026914B1 (pl)
ES (1) ES2637802T3 (pl)
HR (1) HRP20171177T1 (pl)
HU (1) HUE034353T2 (pl)
IL (1) IL240495A0 (pl)
LT (1) LT2961391T (pl)
MA (1) MA38354B1 (pl)
MX (1) MX2015011290A (pl)
NZ (1) NZ709747A (pl)
PE (1) PE20151608A1 (pl)
PH (1) PH12015501701A1 (pl)
PL (1) PL2961391T3 (pl)
PT (1) PT2961391T (pl)
SA (1) SA515360952B1 (pl)
SG (1) SG11201505544RA (pl)
SI (1) SI2961391T1 (pl)
TN (1) TN2015000310A1 (pl)
WO (1) WO2014132205A1 (pl)
ZA (1) ZA201504863B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
SI2890687T1 (sl) * 2012-08-30 2017-10-30 Novartis Ag Soli benzotiazolonske spojine kot agonist beta-2-adrenoceptorja
WO2014132205A1 (en) * 2013-02-28 2014-09-04 Novartis Ag Formulation comprising benzothiazolone compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
WO2005110990A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102009003975A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
JO3192B1 (ar) * 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
WO2014132205A1 (en) * 2013-02-28 2014-09-04 Novartis Ag Formulation comprising benzothiazolone compound

Also Published As

Publication number Publication date
DK2961391T3 (en) 2017-09-04
CL2015001940A1 (es) 2015-10-30
HK1212213A1 (en) 2016-06-10
JP2016510020A (ja) 2016-04-04
EP2961391A1 (en) 2016-01-06
AU2014222362A1 (en) 2015-07-23
HRP20171177T1 (hr) 2017-10-06
MA38354A1 (fr) 2016-02-29
EA201591577A1 (ru) 2015-12-30
ZA201504863B (en) 2016-06-29
IL240495A0 (en) 2015-09-24
PE20151608A1 (es) 2015-11-19
NZ709747A (en) 2018-04-27
MA38354B1 (fr) 2016-09-30
AU2014222362B2 (en) 2016-07-21
PH12015501701A1 (en) 2015-10-12
EA026914B1 (ru) 2017-05-31
ES2637802T3 (es) 2017-10-17
EP2961391B1 (en) 2017-05-17
CN104968337A (zh) 2015-10-07
JP2018035186A (ja) 2018-03-08
US20160000761A1 (en) 2016-01-07
PT2961391T (pt) 2017-08-29
SG11201505544RA (en) 2015-09-29
SI2961391T1 (sl) 2017-08-31
CY1119202T1 (el) 2018-02-14
US9623012B2 (en) 2017-04-18
WO2014132205A1 (en) 2014-09-04
JP6230626B2 (ja) 2017-11-15
CA2897565A1 (en) 2014-09-04
LT2961391T (lt) 2017-07-25
SA515360952B1 (ar) 2016-07-10
TN2015000310A1 (en) 2017-01-03
KR20150120386A (ko) 2015-10-27
MX2015011290A (es) 2015-12-03
BR112015020059A2 (pt) 2017-07-18
HUE034353T2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
IL249517A0 (en) A compound that inhibits trk
IL244346A0 (en) Compounds useful as immunomodulators
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
GB201302368D0 (en) Compound
EP2970924A4 (en) PHYTASEFORMULIERUNG
ZA201507044B (en) Pyridinylpyrazoloquinoline compound
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201320432D0 (en) Novel formulation
GB201322948D0 (en) Improved formulation
GB201317718D0 (en) Novel formulation
EP2948457A4 (en) COMPOUNDS
IL240495A0 (en) A preparation containing a benzothiazolone compound
GB2517232B (en) Formulation
GB201306794D0 (en) Compounds
GB201408643D0 (en) Compound
GB201307331D0 (en) Compound
GB201319352D0 (en) Formulation
GB201312347D0 (en) Formulation
GB201317717D0 (en) Novel formulation
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound